StockData

Immunocore vs Novavax

IMCR and NVAX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IMCR and NVAX compare

Immunocore and Novavax are about the same size, with market caps of $1.4B and $1.3B.

Immunocore grew revenue faster over the last twelve months (21.0% versus −61.6% for Novavax).

Immunocore keeps more of each dollar of sales as profit, with a net margin of −4.2% compared with −59.9% at Novavax.

Immunocore scores higher on the StockData Score (7 against 4 for Novavax), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIMCRNVAX
Size and price
Market cap$1.4B$1.3B
Share price$27.81$7.96
Change, 1 year−22.6%14.2%
Change, 5 years−23.6%−96.3%
Beta (5Y)0.191.72
Employees524749
StockData Score
Total score7 (better)4
Valuation score11
Growth score2 (better)1
Performance score3 (better)1
Health score11
Dividend score00
Valuation
P/S3.3×3.2× (better)
P/B3.4×–
FCF yield−2.9%–
Fair value$32.29–
Margin of safety13.9%–
Growth
Revenue growth (TTM)21.0% (better)−61.6%
Revenue growth, 5Y average–18.8%
Net income growth (TTM)–−159%
EPS growth (TTM)–−168%
Profitability
Gross margin98.9% (better)78.6%
Operating margin−5.2% (better)−56.6%
Net margin−4.2% (better)−59.9%
FCF margin−9.6%–
Return on equity−4.5%–
Financial health
Interest coverage−1.8× (better)−10.7×
Current ratio4.47 (better)2.33
Altman Z-score1.40 (better)−5.92
Piotroski F-score36 (better)
Dividends and buybacks
Dividend yield0.00%–
Years of dividend growth0–
Shareholder yield0.00%0.00%
Ownership
Held by institutions102%71.2%
Held by insiders15.5%9.2%
Insider net buying, 12 months−$1.9M–
Superinvestors holding–1
Short interest, % of float–30.9%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.